ProShares Ultra NASDAQ Biotechnology
34 hedge funds and large institutions have $25.3M invested in ProShares Ultra NASDAQ Biotechnology in 2020 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 5 closing their positions.
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
58% more call options, than puts
Call options by funds: $8.66M | Put options by funds: $5.47M
36% more capital invested
Capital invested by funds: $18.6M → $25.3M (+$6.7M)
13% more funds holding
Funds holding: 30 → 34 (+4)
1.45% more ownership
Funds ownership: 9.01% → 10.46% (+1.5%)
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
+$7.47M |
| 2 |
HF
HRT Financial
New York
|
+$1.16M |
| 3 |
JIC
Johnson Investment Counsel
Cincinnati,
Ohio
|
+$232K |
| 4 |
SIA
Soltis Investment Advisors
St. George,
Utah
|
+$213K |
| 5 |
Jane Street
New York
|
+$199K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.47M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.59M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$850K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$322K |
| 5 |
PGCM
Prescott Group Capital Management
Tulsa,
Oklahoma
|
-$210K |
BIB Hedge Fund Activity: Q4 2020 in Review
34 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q4 2020, worth a combined $25.3M — up 36% from $18.6M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new BIB positions and 5 closed out — a net gain of 4 holders — while 4 added to existing stakes and 9 trimmed.
The largest buyer was Sowell Financial Services, adding an estimated $7.47M. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $3.47M sold.
- 34 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q4 2020, up from 30 in Q3 2020.
- Funds reported $25.3M of ProShares Ultra NASDAQ Biotechnology stock for Q4 2020, up 36% quarter-over-quarter.
- 9 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q4 2020 and 5 closed out, a net change of +4 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q4 2020 was Sowell Financial Services, an estimated $7.47M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q4 2020 was Tower Research Capital (TRC), an estimated $3.47M sold.
Based on aggregated 13F filings for Q4 2020.